CFDA’s Approval Of Gilupi’s CellCollector for In-Vivo CTC Isolation Signifies The Importance of Partnership Between International Medical Device Manufacturers and Chinese Local Firms

Share:

To enter the Chinese market, partnership forged between international medical device manufacturers and local Chinese firms is on the rise. In such partnership, the medical device companies are working with local Chinese firms to accelerate CFDA regulatory process, China market commercialization and sometimes also to obtain needed growth capital and local manufacturing and distribution.

As a recent example of this type of partnership, CFDA has approved CellCollector® manufactured by Gilupi, a medical device for in vivo CTC isolation. Gilupi, the Potsdam, Germany-based company now gains access to one of the most significant geographical markets worldwide. This significant market development success by Gilupi was reached in partnership with with its strategic partner, Hebei Viroad Biotechnology (Viroad). Besides its role as a strategic partner, Viroad is also the largest investor and shareholder of Gilupi.

 


About China Med Device, LLC (CMD) CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at info@ChinaMedDevice.com.

Related Posts